New Targeted Drug Approved for Low-Grade Glioma in Kids
(MedPage Today) -- The FDA granted accelerated approval to tovorafenib (Ojemda) for children 6 months and up with relapsed or refractory low-grade glioma and BRAF-altered tumors, the agency announced on Tuesday.
It represents the first systemic...
Source: MedPage Today Public Health - Category: American Health Source Type: news
More News: American Health | Brain Tumor | Children | Glioma | International Medicine & Public Health